Miguel Secures Prestigious Arthritis UK Grant to Transform Early Diagnosis

We are delighted to celebrate the success of Dr Miguel Pineda, who has been awarded a highly competitive Arthritis UK Early Detection and Targeted Treatment Grant. This three‑year project will pioneer a new, rapid, and precise method for identifying the specific type of inflammation present in arthritis—helping clinicians move beyond today’s trial‑and‑error approach to treatment.

Arthritis currently affects more than 10 million people in the UK, and effective treatment depends on understanding the underlying inflammatory processes. Miguel’s project aims to address this challenge by combining Raman spectroscopy, an advanced light‑based technique that reveals subtle chemical differences in cells and tissues, with artificial intelligence.

A major focus of the research is analysing changes in cell‑surface sugar molecules, which play an important role in regulating immune responses. By capturing these molecular signatures and using AI to classify them, the project seeks to deliver a fast, non‑invasive tool to accurately diagnose arthritis subtypes.

This award recognises Miguel’s innovative approach to tackling a significant clinical need and highlights the potential for stronger collaboration between CeMi researchers and Arthritis UK.

Congratulations, Miguel, on this fantastic achievement. We look forward to seeing this work progress and to the impact it will have on arthritis diagnosis and patient care.